BioSpace News Archive

The latest market analysis report published by Reports and Data, titled ‘Global Macular Degeneration Market – Forecast to 2030,’ thoroughly examines the Macular Degeneration industry to provide essential data & information for the targeted readers.

The latest market analysis report published by Reports and Data, titled ‘Global Malignant Melanoma Market – Forecast to 2030,’ thoroughly examines the Malignant Melanoma industry to provide essential data & information for the targeted readers.

The latest market analysis report published by Reports and Data, titled ‘Global Neuroblastoma Market – Forecast to 2030,’ thoroughly examines the Neuroblastoma industry to provide essential data & information for the targeted readers.

The global clinical decision support system market size was USD 4.48 Billion in 2021 and is expected to register a revenue CAGR of 10.3% during the forecast period, according to latest analysis by Emergen Research.

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) (“Hemostemix” or the “Company”) is pleased to announce the appointment of Dr. Nadia Giannetti, MD, to its Scientific Advisory Board.

AltruBio Inc. announced that AltruBio President and CEO Dr. Judy Chou will speak on “The Next Wave of Targeted Therapies” at the Longwood Healthcare Leaders Fall Webconference on Wednesday, September 21, 2022.

Defence Therapeutics Inc., a Canadian biotech company actively working on accelerating scientific discoveries and products development against cancer, congratulates the US President Joe Biden for the executive order signed on Monday establishing the Biotechnology and Biomanufacturing initiative to ensure cutting-edge biotechnologies necessary to end cancer as we know it, and other innovations to be developed and manufactured in America.

Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved the fixed-dose combination of Opdualag (nivolumab and relatlimab) for the first-line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumor cell PD-L1 expression < 1%.

Predictive Oncology announced that J. Melville Engle will retire as Chief Executive Officer and as Chairman and a member of the company’s Board of Directors.

Ocugen, Inc. announced the Compensation Committee of the Board of Directors of Ocugen approved the grant of stock options to purchase an aggregate of 148,800 shares of its common stock and restricted stock units covering an aggregate of 40,092 shares of common stock to five newly hired team members.